Uroprost-D (Suppositories) Instructions for Use

Marketing Authorization Holder

Patent-Pharm, JSC (Russia)

Manufactured By

Altpharm LLC (Russia)

ATC Code

G04BX (Other drugs for the treatment of urological diseases)

Active Substance

Prostate extract (Grouping name)

Dosage Form

Uroprost-D

Rectal suppositories 6 mg: 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Rectal suppositories semi-transparent with possible marbling, almost colorless or with a yellowish or grayish tint, torpedo-shaped; a slight softening of the surface layer and “sweating” of the contour cell packaging is allowed; the presence of an air rod or a funnel-shaped depression is allowed.

Excipients: dimethyl sulfoxide – 90 mg, macrogol 1500 (polyethylene oxide 1500) – to obtain a suppository weighing 2300 mg.

5 pcs. – contour cell packaging (1) – cardboard packs.
5 pcs. – contour cell packaging (2) – cardboard packs.

Clinical-Pharmacological Group

Drug of animal origin used for prostate diseases

Pharmacotherapeutic Group

Drugs used in urology; other drugs used in urology

Pharmacological Action

A drug of animal origin. It has an organotropic effect on the prostate gland.

It reduces the degree of edema, leukocyte infiltration of the prostate gland, normalizes the secretory function of epithelial cells, increases the number of lecithin grains in the secretion of acini, and stimulates the muscle tone of the bladder.

It reduces thrombus formation, has antiplatelet activity, and prevents the development of venule thrombosis in the prostate gland.

It normalizes the parameters of the prostate gland and ejaculate.

Pharmacokinetics

As a peptide substance, it is broken down by cellular proteases into amino acids. It does not have a cumulative effect.

Indications

Chronic prostatitis; benign prostatic hyperplasia; conditions before and after surgical interventions on the prostate gland.

ICD codes

Dosage Regimen

Use rectally in adult men only.

Administer one 6 mg suppository twice daily.

Insert the suppository deeply into the rectum after bowel evacuation.

For chronic prostatitis, the standard treatment course is 10 days.

For benign prostatic hyperplasia, the treatment course is 15 days.

Repeat courses of treatment are possible as prescribed by a physician.

For pre-operative and post-operative preparation, follow the specific regimen prescribed by the surgeon.

Perform analysis of prostate secretion before initiating treatment for chronic prostatitis.

Ensure a benign pathology diagnosis before treating benign prostatic hyperplasia.

Conduct standard monitoring of the disease during therapy.

Discontinue use and consult a physician if signs of an allergic reaction appear.

Adverse Reactions

Allergic reactions very rarely – urticaria.

Contraindications

Hypersensitivity to the active substance; age under 18 years.

Use in Pregnancy and Lactation

Not applicable.

Pediatric Use

Contraindicated for use under the age of 18 years.

Special Precautions

Before starting treatment for chronic prostatitis and, if necessary, during treatment, it is recommended to perform an analysis of the prostate secretion.

During the use of the drug for the treatment of benign prostatic hyperplasia, standard monitoring of this disease should be regularly performed. Before starting treatment, it is necessary to ensure that the pathology is benign.

Drug Interactions

Compatible with antibacterial drugs used to treat prostatitis.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.